Roth/MKM Resumes Fortress Biotech (FBIO) at Buy, 'has successfully spun out four public companies'
Tweet Send to a Friend
Roth/MKM analyst Jason Whittes resumes coverage on Fortress Biotech (NASDAQ: FBIO) with a Buy rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
